A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), the commonest cancer in childhood and one that can be particularly difficult to treat in older patients, according to Cambridge scientists.
Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukaemia in people at high risk of the disease, a study in mice has suggested. Further research in clinical trials will be needed to confirm this works for patients.
Researchers have discovered a way to extend the shelf life of blood stem cells outside the body for use in gene therapy, providing patients with better options and improving their outcomes.
Combining three different sources of genetic information has allowed researchers to further understand why only some people with a common mutation go on to develop rare blood cancer.
The new ‘MN-predict’ platform will allow doctors and scientists to identify those at risk and to design new treatments to prevent them from developing these potentially lethal cancers.
Eight researchers from the University of Cambridge have won European Research Council (ERC) Consolidator Grants
Cambridge researchers are taking part in the world’s first clinical trial of red blood cells that have been grown in a laboratory for transfusion into another person.
Five University of Cambridge researchers have been awarded Consolidator Grants from the European Research Council, the premier European funding organisation for excellent frontier research.
Cambridge scientists are among the new Fellows announced today by the Academy of Medical Sciences.
Cambridge-led study discovers new genetic causes of rare diseases, potentially leading to improved diagnosis and better patient care.
© 2025 University of Cambridge